

OncomiR Passenger Strand Activity? Yuan-Yuan Jin, Jade Andrade, Nicole L. Simone, and Eric Wickstrom Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia PA 19107

-15.2



ABSTRACT

We hypothesized that knocking down the oncogenic microRNA (oncomiR) miR-17-5p might restore the expression levels of programmed cell death 4 (PDCD4) and phosphatase and tensin homolog (PTEN) tumor suppressor proteins, illustrating a route to oligonucleotide therapy of TNBC. Contrary to conventional wisdom, we found that antisense DNA-LNA knockdown of miR-17-5p guide strand reduced PDCD4 and

In contrast, 5 putative binding sites for miR-17-3p passenger strand in PDCD4 mRNA, and 6 in *PTEN* mRNA, were predicted. No sites, however, were identified for the passenger strand miR-21-3p.

PASSENGER STRAND SITES



STRUCTURAL PREDICTIONS

WESTERN BLOTS



The structural predictions imply that 3'-UTR mRNA:oncomiR duplexes can be accommodated in the substrate groove of

To determine if the passenger strand was involved in the contradictory results above, we knocked down endogenous miR-17-3p with antimiR-17-3p. The



PDCD4 β-Actin

western blot after miR-17-3p knockdown showed no significant changes in PDCD4 or

PTEN proteins by 1.8±0.3 fold in human triple negative breast cancer (TNBC) cells, instead of raising them. In contrast, antisense DNA-LNA knockdown of miR-17-3p passenger strand maintained PDCD4 and PTEN protein levels. Furthermore, antisense DNA-LNA knockdown of miR-17-3p passenger strand raised PDCD4 mRNA by 25±2% and *PTEN* mRNA by 22±6%.

BACKGROUND

A variety of oncomiRs are overexpressed in TNBC, and are being studied intensively as targets for complementary oligonucleotide therapy.¹ Conventional wisdom holds that only one of the two strands in an oncomiR precursor duplex is selected as the active oncomiR guide strand.² The complementary passenger strand, however, is thought to be inactive.² High levels of the oncomiR guide strand called miR-17-5p can inhibit ribosom translation of tumor suppressor gene mRNAs, such as PDCD4 or PTEN.³ Blockir 3'UTR sites depresses initiation of *PDCD4* PTEN mRNA translation in TNBC cells, interdicting tumor suppression.^{4,5}

Ago2, despite the mismatches and bulges that appear so distorted in the Mfold presentation. Our result agrees with an earlier simulation of an 11mer duplex bound to Thermus thermophilus Ago.¹⁰ MMPBSA calculations⁹ predicted favorable ΔG° for each duplex formation, as did Mfold.¹¹

ONCOMIR KNOCKDOWN

Anti-miR-17-5p DNA-LNA chimera (Exigon) transfected into MDA-MB-231 TNBC cells knocked down miR-17-5p by 99±0.01% after 12 hr (left). Similarly, anti-miR-21-5p transfected into MDA-MB-231 TNBC cells knocked down miR-17-5p by 99±0.04% (right). The oncomiRs were knocked down.



PTEN protein levels. The static result is plausible, because there are 5-6 potential binding sites for miR-17-3p on PDCD4 and PTEN mRNAs, vs. one for miR-17-5p.

CONCLUSIONS

We concluded that anti-miR-17-5p guide strand mimicked miR-17-3p passenger strand, effectively raising the miR-17-3p concentration in TNBC cells.

5' <mark>A-CUGCA</mark>G<mark>UG</mark>-AAGGCAC-UUG</mark>UAG 3' miR-17-3p 5' ACCTGCACTGTAAG-CACTTTG 3' Anti-miR-17-5p

CA<mark>AAGUGC-UU-AC</mark>AG<mark>UGCAG</mark>GUAG 3' miR-17-5p 5' TAC-<mark>AAGTGC</mark>C<mark>TT</mark>C<mark>AC</mark>--<mark>TGCAG</mark> 3' Anti-miR-17-3p Our results imply that therapeutic antisense sequences against oncomiRs should be designed to target the oncomiR strand with the greatest number of putative binding sites in the target mRNAs. Precaution must be taken when designing oncomiR knockdown sequences as potential therapeutic or diagnostic agents, since both the guide strand and the passenger strand of a oncomiR might target the same transcript. Both strands act.

miR-17 HAIRPIN					
	miR-17-5p				
ga	-ca ag g-au				
guca auaaug	n aagugcuu ca ugcag uag ug a				
1111 11111	u				
cagu uauuac	g uucacgga gu acguc a <mark>uc ac g</mark>				
gg	aug a g - u gu				

		G A GAAGU	
1110-11 36	miRanda	5'-UUUAAAC AAAUA G C UGCC UU ACUGCAG ACGG AA UGACGUC GAUGUUC G A-5'	-14.1
aThe pot miRanda Top stra	ential oncor a. and is mRN/	miR:mRNA binding sites were identified by A (5' \rightarrow 3') and the bottom strand is oncomily (mfold records on the bottom strand is oncomily (mfold records on the bottom).	rna22, Targetscan, or R (3'→5').
Predicte	ed miR-17-3	p passenger strand binding sites in the 3'L	JTR of <i>PTEN</i> mRNA
Site	Algorithma	Mfold Predicted Structure ^b	Mfold ^c Δ G [°] , kcal/mol
3768-37 89	rna22	5'-CUAU - AA UACAA UG UUU UGCAGU AUGUU AC AAG ACGUCA-5' G C GG UG	-11.9
7644-76 65	rna22	A AGA A 5'-ACAG UGC UUAC UGUAGU UGUU ACG AGUG ACGUCA-5' GA C GA	-14.4
8937-84 18	rna22	5'-GGAAUG AG U AAGUG GCU GUAGU UUCAC UGA CGUCA-5' GAUG GGAAG	-10.0
8440-84 61	rna22	5'-UGC - G CAAGU CU UUUACUGCAGU GUUCA GG AAGUGACGUCA-5' GAU C	-19.8
8477-84 98	rna22	5'-UUU U G - C CAG GUG UUUU CUGUAG GUU CAC GAAG GACGUC GAU - G U A-5'	-11.7
8628-86 49	rna22	5'-CC - U - AAUG CU CA GU CCU UGCAGU GA GU CA GGA ACGUCA-5'	-11.1

UUGCAGU

GACGUCA-5'

rna22

336

5'-C G - AGAGG

CUG GAG GC

GAU UUC CG



Mock transfected

Anti-miR-21

Mock transfected

Anti-miR-17-5p

evaluate whether miR-17-5p had any ffect on the expression level of PDCD4 rotein, we transfected anti-miR-17-5p into IDA-MB-231 TNBC cells and analyzed rotein levels 48 hr after transfection. urprisingly, the PDCD4 protein and PTEN rotein levels were down-regulated by .8±0.3 fold, instead of being up-regulated as xpected following miR-17-5p knockdown. his result conflicted with the expectation that

REFERENCES

¹ Calin, G.A. and Croce, C.M. (2006) *Cancer*, **6**, 857-866. ² Khvorova, A., Reynolds, A. and Jayasena, S.D. (2003) *Cell* **115**, 209-216.

³ Xiao, C., Srinivasan, L., Calado, D.P., Patterson, H.C., Zhang, B., Wang, J., Henderson, J.M., Kutok, J.L. and Rajewsky, K. (2008) Nature Immunology 9, 405-414. ⁴ Dong, G., Liang, X., Wang, D., Gao, H., Wang, L., Wang, L., Liu, J. and Du, Z. (2014) *Medical Oncology* **31**, 1-10.

⁵ Frankel, L.B., Christoffersen, N.R., Jacobsen, A., Lindow, M., Krogh, A. and Lund, A.H. (2008) Journal of *Biological Chemistry* **283**, 1026-1033.

⁶ Loher, P. and Rigoutsos, I. (2012) *Bioinformatics* **28**,

miR-17-3p

IN SILICO TARGET SEARCHES

We sought an answer to the knockdown contradiction by applying 3 different oncomiR target prediction algorithms, rna22⁶, TargetScan⁷, and miRanda⁸ to search for PDCD4 and PTEN mRNA targets of oncomiRs miR-17 and miR-21. Sequence scanning yielded only one miR-17-5p guide strand site in *PDCD4* or *PTEN* mRNA. OncomiR miR-21-5p can bind two 3'UTR targets in PDCD4 and a single target in PTEN mRNA.

^aThe potential oncomiR:mRNA binding sites were identified by rna22, Targetscan, r miRanda. Top strand is mRNA (5' \rightarrow 3') and the bottom strand is oncomiR (3' \rightarrow 5'). Calculated at http://mfold.rna.albany.edu/?q=mfold.

MOLECULAR DYNAMICS

We simulated all predicted 3'-UTR mRNA:oncomiR duplexes, for both guide strands and passenger strands. We calculated 50 ns accelerated molecular dynamics of each duplex in explicit H₂O with 100 mM NaCl with AMBER 12.9 Our molecular dynamics calculations predicted stable A-form duplexes for all oncomiR passenger strand:mRNA targets, as well as for guide strands.

niR-17-5p target expression would increase when miR-17-5p was knocked down. AntimiR-21-5p, however, behaved as expected, elevating PDCD4 and PTEN protein levels.



3322-3323.

⁷ Lewis, B.P., Burge, C.B. and Bartel, D.P. (2005) *Cell* **120**, 15-20.

⁸ Enright, A.J., John, B., Gaul, U., Tuschl, T., Sander, C. and Marks, D.S. (2003) Genome Biology 5, R1. ⁹ Sanders, J. M., Wampole, M. E., Chen, C.-P., Sethi, D., Singh, A., Dupradeau, F.Y., Wang, F., Gray, B.D., Thakur, M. L., and Wickstrom, E. (2013) Journal of Physical *Chemistry B* **117**:11584-11595. ¹⁰ Xia, Z., Clark, P., Huynh, T., Loher, P., Zhao, Y., Chen, H.W., Ren, P., Rigoutsos, I., and Zhou, R. (2012)

Scientific Reports **2**(569), 1-9. ¹¹ Zuker, M. (2003) Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Research* **31**, 3406-3415.

SUPPORTED BY NIH CA148565. IP: pending US patent application 61/938,776